Cyclacel Pharmaceuticals has entered into a definitive agreement to sell four of its patents related to the use of the romidepsin injection to Celgene Corporation.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Cyclacel, Celgene, romidepsin, patent sale